



PRESS RELEASE

CYNBIOSE RESPIRATORY, A NEW CRO SPECIALIZED IN RESPIRATORY DISEASES AND AEROSOL THERAPY, ANNOUNCES THE BEGINNING OF ITS OPERATIONS

- Created on the basis of existing know-how shared by its co-founders: the company Cynbiose (Marcy l'étoile, France) specialized in innovative preclinical models and the academic Research Center for Respiratory Diseases-INSERM UMR 1100 (Tours, France) which contribute to the discovery and development of new treatments in this therapeutic area, Cynbiose Respiratory (Tours, France) is an hyper-specialized CRO
- Cynbiose Respiratory's ambition is to become a global leader in preclinical evaluation of respiratory treatments and aerosol therapy

Tours, France, January 25th 2018 – Cynbiose Respiratory, a contract research organization (CRO) providing a set of innovative technologies and preclinical services to assess drugs pharmacology and efficacy in the area of respiratory diseases and aerosol therapy, today announces the beginning of its operations. Beside preclinical evaluation, Cynbiose Respiratory also provides a full service of formulation for aerosol therapy, including nebulizer signature and *in vivo* PK/PD characterizations. Incorporated in August 2017, the company is already delivering fee-based services to the healthcare industry for the preclinical development of prophylactic and therapeutic drug candidates. Its clients cover from academic to industry, from therapeutics to medical devices.

"With the creation of Cynbiose Respiratory, Cynbiose and the Research Center for Respiratory Diseases-INSERM UMR 1100 now combine a huge and unique preclinical evaluation expertise in the field of respiratory diseases and aerosol therapy. As founder and expert in service industry, we are convinced of the role and benefit of hyper-specialized CRO structures, like Cynbiose Respiratory, to serve research teams from academia to industry and accelerate the development of therapeutic innovations", said Hugues Contamin, co-founder and CEO of Cynbiose and Cynbiose Respiratory.

Mustapha Si-Tahar, Head of the Research Center for Respiratory Diseases-INSERM UMR 1100 and co-founder, added: *"we would like to thank all the collaborative partners as well as the public funding agencies in Tours and Region Centre, which helped the creation of Cynbiose Respiratory. A few months after inception, we already have first contracts and contacts validating our positioning and the need we can address"*.

Nathalie Heuzé-Vourc'h, one of the most renowned scientist in the field of inhaled biotherapeutics and co-founder, said: *"I'm proud to be part of this new venture. At the Research Center for Respiratory Diseases-INSERM UMR 1100, we were not able to face all the requests coming from the industry, neither to develop dedicated services. Cynbiose Respiratory is a huge asset for both research institutions and biotech and biopharma companies developing inhaled therapeutics and aerosol devices"*.

Samuel Salot, General Manager and co-founder of Cynbiose Respiratory, concluded: *“with a broad offer, we aim at becoming a global leader in preclinical evaluation of inhaled drugs and therapeutic drug candidates. We can respond to specific requests as well as routine assays from the formulation of biologics or chemical entities for aerosol delivery to their in vivo assessment. This is a tremendous added value in a context of impressively growing demand in this area of inhaled drugs¹”*.

About Cynbiose - www.cynbiose.com

Cynbiose is a unique service company that aims to develop and commercialize innovative models in non-human primate species to accelerate and secure the preclinical phases of drug candidate development. Cynbiose implements exploratory studies and also develops pharmacological models in several therapeutic areas to establish a strong link between preclinical development and clinical phases.

About the Research Center for Respiratory Diseases INSERM UMR 1100 - www.cepr.inserm.univ-tours.fr

The Research Center for Respiratory Diseases INSERM UMR 1100 aims at achieving a better understanding of the pathophysiology of respiratory diseases and formulating more effective devices for targeted therapy. Respiratory diseases have a significant impact from a medical and socioeconomic viewpoint. Despite this critical situation, the existing treatments are limited as they relieve some symptoms, but are seldom curative. This is precisely the mission that the CEPR has set itself by contributing to the discovery and development of new treatments in this therapeutic area.

Contacts:

Cynbiose Respiratory

Samuel SALOT, General Manager

Tel: +33 6 78 77 81 94

samuel.salot@cynbiose-respiratory.com

ATCG Partners / Press Relations

Marie Puvieux

Mob: +33 (0)6 10 54 36 72

presse@atcg-partners.com

cynbiose-respiratory.com

¹ The Stock Radio: <https://www.prnewswire.com/news-releases/global-market-for-inhaled-drugs-rapidly-growing-300295244.html>